Germany's G-BA confirms added benefit of Kisplyx

The German Federal Joint Committee (G-BA) has confirmed the additional benefit of Kisplyx (lenvatinib) in combination with everolimus for the treatment of adults with advanced renal cell carcinoma (RCC) versus everolimus alone.

With this decision, the G-BA followed the recommendation of the German Institute for Quality and Efficiency in Health Care (IQWiG) published on January 2, 2017 thereby also affirming that the data presented by Japanese pharma major Eisai (TYO 4523) provided convincing evidence of a clinically meaningful added survival benefit for the combination.

"The G-BA decision is encouraging for clinicians and patients alike. In Study 205, patients treated with lenvatinib in combination with everolimus [Novartis’ Afinitor] showed a median progression free survival of 14.6 months, which is far more than the clinical community expected to see in the second line RCC setting. This underscores the pivotal role that tyrosine kinase inhibitors still play in treating these patients," comments Professor Dr med Viktor Grünwald, of the Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Germany.